Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

64.79 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
38 39 Next >
AstraZeneca Stock Gains As Q2 Earnings Beat Forecasts, Clocks $894M In COVID-19 Vaccine Sales
AstraZeneca plc (NASDAQ: AZN) COVID vaccine generated $894 million in sales in Q2. The group added that it shipped about 319 million doses worldwide during 1H of 2021,... 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
FDA approval of roxadustat seems unlikely. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis Product Safety
7 Stocks To Watch For July 29, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Mastercard Inc (NYSE: MA) to report quarterly earnings at $1.72 per share on revenue of $4.34... 
Via Benzinga
No Increased Risk Of Blood Clots After Second Dose Of AstraZeneca's COVID-19 Shot, Study Shows
A person's risk of blood clots does not increase after the second Oxford/AstraZeneca plc (NASDAQ: AZN) COVID-19 vaccine shot. The Company is trying to boost... 
Via Benzinga
Exposures COVID-19
Understanding AstraZeneca's Unusual Options Activity
AstraZeneca (NASDAQ:AZN) shares experienced unusual options activity on Wednesday. The stock price moved down to $57.28 following the option alert. Sentiment: BEARISH Option... 
Via Benzinga
Hutchmed Stock Gains On Kick Starting Mid-Stage Gastric Cancer Trial With AstraZeneca's Orpathys
HUTCHMED (China) Limited (NASDAQ: HCM) and AstraZeneca Plc (NASDAQ: AZN) have initiated a Phase 2 study of Orpathys (savolitinib) in patients with... 
Via Benzinga
South Korean Study Also Shows Mixed Regime Of COVID-19 Jabs Boosts Antibody Levels: Reuters
A South Korean study, mixed vaccination of first AstraZeneca plc’s (NASDAQ: AZN) jab followed by the Pfizer Inc (NYSE: PFE) - BioNTech SE (... 
Via Benzinga
Exposures COVID-19
EMA's CHMP Backs AstraZeneca's Drug For Rare Blood Disorder In Children
AstraZeneca Plc (NASDAQ: AZN) said that the European Medicines Agency (EMA) has recommended approving a medicine from its recently acquired Alexion for a rare, deadly blood... 
Via Benzinga
These Companies Have Seen Large Returns From 2020 Government Investment
Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal... 
Via Benzinga
Analyzing AstraZeneca's Unusual Options Activity
On Friday, shares of AstraZeneca (NASDAQ:AZN) saw unusual options activity. After the option alert, the stock price moved up to $58.23. Sentiment: BULLISH Option Type: SWEEP... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
AstraZeneca's Once-Weekly Diabetes Med Wins FDA Nod For Use In Children
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Budureon BCise (exenatide extended-release), once-weekly injectable suspension for type 2 diabetes (T2D)... 
Via Benzinga
Exposures Product Safety
Real-World Data In Canada Shows AstraZeneca's COVID-19 Jab Is Over 80% Effective Against Variants
Results from the Canadian Immunization Research Network (CIRN) showed that one dose of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine was 82% effective... 
Via Benzinga
Exposures COVID-19
Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant
Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing... 
Via Benzinga
The Cloud Sector Can Drive Your Profits Sky High
If you hear someone suggesting you invest in “containers,” please don’t get confused. Most folks would naturally think of these as giant metal shipping boxes that are integral for global trade. 
Via Talk Markets
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat... 
Via Benzinga
Exposures Product Safety
Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms
Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster... 
Via Benzinga
Aridis In-Licenses Pneumonia Candidate From AstraZeneca
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has entered into an exclusive, worldwide licensing agreement with AstraZeneca plc (NASDAQ: AZN) to in-license the... 
Via Benzinga
China Approves AstraZeneca's Imfinzi For Extensive-Stage Small Cell Lung Cancer
National Medical Products Administration of China has approved AstraZeneca plc's (NASDAQ: AZN) Imfinzi (durvalumab) to treat an aggressive type of lung cancer... 
Via Benzinga
AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?
Probably so. 
Via The Motley Fool
With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?
With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21. 
Via The Motley Fool
Weak Week
Friday tried a recovery because retail sales data for June were strong, particularly in dining out, although in the end, the weak tech side cut the optimism. 
Via Talk Markets
Jon Najarian Sees Unusual Options Activity In AstraZeneca And Home Depot
On CNBC's "Fast Money Halftime Report," Jon Najarian said he saw people buying aggressively the December $60 calls in AstraZeneca plc (NASDAQ: AZN). He likes the... 
Via Benzinga
MRNA Surges to Record High on Plans to Join S&P 500
Moderna stock is set to join the benchmark on July 21, replacing Alexion Pharmaceuticals. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Moderna Stock — Soon To Join S&P 500 — Rockets To Yet Another Record
Moderna stock rocketed to another record high Friday on news it would join the S&P 500 on Wednesday, replacing soon-to-be-acquired Alexion. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Unusual Options Activity Insight: AstraZeneca
AstraZeneca (NASDAQ:AZN) shares experienced unusual options activity on Friday. The stock price moved down to $56.77 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
Why Moderna Stock Just Jumped 10%
The company joins the S&P 500 index next week. 
Via The Motley Fool
Topics Stocks
Exposures COVID-19 US Equities
MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500
Moderna (MRNA) stock is on the rise Friday as the company prepares to join the S&P 500 next week replacing Alexion Pharmaceuticals (ALXN). 
Via InvestorPlace
Topics Stocks
Exposures US Equities
FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment
A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday. 
Via Investor's Business Daily
Exposures Product Safety
GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies
GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.